AU2020348436A1 - Recombinant human neuregulin derivatives and use thereof - Google Patents

Recombinant human neuregulin derivatives and use thereof Download PDF

Info

Publication number
AU2020348436A1
AU2020348436A1 AU2020348436A AU2020348436A AU2020348436A1 AU 2020348436 A1 AU2020348436 A1 AU 2020348436A1 AU 2020348436 A AU2020348436 A AU 2020348436A AU 2020348436 A AU2020348436 A AU 2020348436A AU 2020348436 A1 AU2020348436 A1 AU 2020348436A1
Authority
AU
Australia
Prior art keywords
ser
val
lys
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020348436A
Other languages
English (en)
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010955006.XA external-priority patent/CN112500493A/zh
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of AU2020348436A1 publication Critical patent/AU2020348436A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020348436A 2019-09-16 2020-09-14 Recombinant human neuregulin derivatives and use thereof Pending AU2020348436A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910873003 2019-09-16
CN201910873003.9 2019-09-16
CN202010955006.X 2020-09-11
CN202010955006.XA CN112500493A (zh) 2019-09-16 2020-09-11 重组人神经调节蛋白衍生物及其用途
PCT/CN2020/114955 WO2021052277A1 (zh) 2019-09-16 2020-09-14 重组人神经调节蛋白衍生物及其用途

Publications (1)

Publication Number Publication Date
AU2020348436A1 true AU2020348436A1 (en) 2022-04-07

Family

ID=74883174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020348436A Pending AU2020348436A1 (en) 2019-09-16 2020-09-14 Recombinant human neuregulin derivatives and use thereof

Country Status (7)

Country Link
US (1) US20230057622A1 (https=)
EP (1) EP4032901A4 (https=)
JP (2) JP2022547335A (https=)
KR (1) KR20220066116A (https=)
AU (1) AU2020348436A1 (https=)
CA (1) CA3157354A1 (https=)
WO (1) WO2021052277A1 (https=)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU745324B2 (en) 1997-10-14 2002-03-21 Cenes Pharmaceuticals, Inc. Therapeutic methods comprising use of a neuregulin
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
GB201313235D0 (en) * 2013-07-24 2013-09-04 Univ Edinburgh Antiviral Compositions Methods and Animals
CN110946993A (zh) * 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) * 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
CN108623672A (zh) * 2017-03-25 2018-10-09 成都贝爱特生物科技有限公司 新的egf-a和b的组合突变体制备及其在生物药物中的应用
AU2019209770B2 (en) * 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
FI3774859T3 (fi) * 2018-04-11 2024-05-24 Salubris Biotherapeutics Inc Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät

Also Published As

Publication number Publication date
WO2021052277A1 (zh) 2021-03-25
KR20220066116A (ko) 2022-05-23
JP2025186253A (ja) 2025-12-23
CA3157354A1 (en) 2021-03-25
US20230057622A1 (en) 2023-02-23
EP4032901A1 (en) 2022-07-27
JP2022547335A (ja) 2022-11-11
EP4032901A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CN102232084B (zh) 纽兰格林及其用途
RU2547592C2 (ru) ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА αvβ3, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛЕВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
US8158589B2 (en) Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
AU2011298556B2 (en) Use of interleukin-22 in treating viral hepatitis
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
CA2425506A1 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
EP3227320B1 (en) Modified fibroblast growth factor 1 (fgf-1) polypeptides with increased binding affinity for heparin and associated methods
AU2010283169B2 (en) Novel peptide and use thereof
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
JP7825894B2 (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
CN112585159B (zh) 神经调节蛋白多肽片段及其用途
EP4032901A1 (en) Recombinant human neuregulin derivatives and use thereof
HK40081680A (en) Recombinant human neuregulin derivatives and use thereof
US20090286729A1 (en) Epidermal Growth Factor Receptor Antagonists and Methods of Use
CN112500493A (zh) 重组人神经调节蛋白衍生物及其用途
KR102801906B1 (ko) 피브릴린 재조합 단백질을 포함하는 줄기세포의 평활근세포로의 분화 촉진용 조성물
AU2026202905A1 (en) Method for preventing, treating or delaying myocardial damage using neuregulin and composition
JP2000086533A (ja) 新規なアレルギー治療剤
KR20240094145A (ko) 연골 재생용 펩타이드 및 이의 용도